Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131


Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2017 Dec 16. pii: S0302-2838(17)31030-8. doi: 10.1016/j.eururo.2017.11.038. [Epub ahead of print]


Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.

Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, Zhau HE, Matusik RJ, Chung LW.

Cancer Res. 2017 Mar 15;77(6):1331-1344. doi: 10.1158/0008-5472.CAN-16-0497. Epub 2017 Jan 20.


SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.

Lu W, Liu S, Li B, Xie Y, Izban MG, Ballard BR, Sathyanarayana SA, Adunyah SE, Matusik RJ, Chen Z.

Oncogene. 2017 Mar;36(10):1364-1373. doi: 10.1038/onc.2016.300. Epub 2016 Nov 21.


Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.

Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R.

Oncotarget. 2016 Sep 20;7(38):61955-61969. doi: 10.18632/oncotarget.11326.


NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.

Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW.

Prostate. 2016 Aug;76(11):1004-18. doi: 10.1002/pros.23195. Epub 2016 May 16.


NF-κB and androgen receptor variant expression correlate with human BPH progression.

Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW.

Prostate. 2016 Apr;76(5):491-511. doi: 10.1002/pros.23140. Epub 2015 Dec 28.


Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.

Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ.

Endocrinology. 2016 Mar;157(3):1094-109. doi: 10.1210/en.2015-1312. Epub 2015 Dec 17.


Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.

Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA 3rd, Smith JA Jr, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ.

Am J Pathol. 2015 May;185(5):1385-95. doi: 10.1016/j.ajpath.2015.01.014.


SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.

Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang Q, Ballard BR, Nakayama KI, Matusik RJ, Chen Z.

Oncotarget. 2015 Jan 20;6(2):771-88.


Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.

Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ.

Oncogene. 2015 Jul;34(28):3700-10. doi: 10.1038/onc.2014.302. Epub 2014 Sep 15.


Activation of Wnt/β-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia.

Valkenburg KC, Yu X, De Marzo AM, Spiering TJ, Matusik RJ, Williams BO.

Prostate. 2014 Nov;74(15):1506-20. doi: 10.1002/pros.22868. Epub 2014 Aug 29.


SOX2 expression in the developing, adult, as well as, diseased prostate.

Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):301-9. doi: 10.1038/pcan.2014.29. Epub 2014 Aug 5.


Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis.

Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ, Chen Z.

Mol Oncol. 2014 Oct;8(7):1355-64. doi: 10.1016/j.molonc.2014.05.006. Epub 2014 May 21.


FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.

DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ.

Lab Invest. 2014 Jul;94(7):726-39. doi: 10.1038/labinvest.2014.64. Epub 2014 May 19.


NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.

Grabowska MM, Elliott AD, DeGraff DJ, Anderson PD, Anumanthan G, Yamashita H, Sun Q, Friedman DB, Hachey DL, Yu X, Sheehan JH, Ahn JM, Raj GV, Piston DW, Gronostajski RM, Matusik RJ.

Mol Endocrinol. 2014 Jun;28(6):949-64. doi: 10.1210/me.2013-1213. Epub 2014 May 6.


NF-κB gene signature predicts prostate cancer progression.

Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA Jr, Matusik RJ.

Cancer Res. 2014 May 15;74(10):2763-72. doi: 10.1158/0008-5472.CAN-13-2543. Epub 2014 Mar 31.


F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder.

Clayton DB, Stephany HA, Ching CB, Rahman SA, Tanaka ST, Thomas JC, Pope JC 4th, Adams MC, Brock JW 3rd, Clark PE, Hayward SW, Matusik RJ, Milne GL.

J Urol. 2014 May;191(5 Suppl):1597-601. doi: 10.1016/j.juro.2013.09.027. Epub 2014 Mar 26.


Tailoring peptidomimetics for targeting protein-protein interactions.

Akram ON, DeGraff DJ, Sheehan JH, Tilley WD, Matusik RJ, Ahn JM, Raj GV.

Mol Cancer Res. 2014 Jul;12(7):967-78. doi: 10.1158/1541-7786.MCR-13-0611. Epub 2014 Mar 18. Review.


Mouse models of prostate cancer: picking the best model for the question.

Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ.

Cancer Metastasis Rev. 2014 Sep;33(2-3):377-97. doi: 10.1007/s10555-013-9487-8. Review.


Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.

Li B, Lu W, Yang Q, Yu X, Matusik RJ, Chen Z.

Prostate. 2014 Apr;74(4):421-32. doi: 10.1002/pros.22763. Epub 2013 Dec 17.


SPARCL1 suppresses metastasis in prostate cancer.

Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, He X, Jin X, Hayward SW, Matusik RJ, George AL Jr, Yi Y.

Mol Oncol. 2013 Dec;7(6):1019-30. doi: 10.1016/j.molonc.2013.07.008. Epub 2013 Jul 20.


Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.

Majumdar S, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, Bellmunt J, Matusik RJ, Rosenberg JE, Adam RM.

Neoplasia. 2013 Jul;15(7):749-60.


Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone.

Jin R, Sterling JA, Edwards JR, DeGraff DJ, Lee C, Park SI, Matusik RJ.

PLoS One. 2013;8(4):e60983. doi: 10.1371/journal.pone.0060983. Epub 2013 Apr 5.


ARF represses androgen receptor transactivation in prostate cancer.

Lu W, Xie Y, Ma Y, Matusik RJ, Chen Z.

Mol Endocrinol. 2013 Apr;27(4):635-48. doi: 10.1210/me.2012-1294. Epub 2013 Feb 28.


Chronic cyclic bladder over distention up-regulates hypoxia dependent pathways.

Stephany HA, Strand DW, Ching CB, Tanaka ST, Milne GL, Cajaiba MM, Thomas JC, Pope JC 4th, Adams MC, Brock JW 3rd, Hayward SW, Matusik RJ, Clayton DB.

J Urol. 2013 Oct;190(4 Suppl):1603-9. doi: 10.1016/j.juro.2013.02.026. Epub 2013 Feb 19.


Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration.

Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW.

Am J Pathol. 2013 Feb;182(2):449-59. doi: 10.1016/j.ajpath.2012.10.007. Epub 2012 Dec 6.


Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.

Gupta A, Yu X, Case T, Paul M, Shen MM, Kaestner KH, Matusik RJ.

Prostate. 2013 May;73(6):582-9. doi: 10.1002/pros.22598. Epub 2012 Oct 11.


Modulation of the hypoxic response following partial bladder outlet obstruction.

Drzewiecki BA, Anumanthan G, Penn HA, Tanaka ST, Thomas JC, Adams MC, Brock JW 3rd, Pope JC 4th, Matusik RJ, Hayward S, Clayton DB.

J Urol. 2012 Oct;188(4 Suppl):1549-54. doi: 10.1016/j.juro.2012.02.037. Epub 2012 Aug 19.


Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.

DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ.

PLoS One. 2012;7(5):e36669. doi: 10.1371/journal.pone.0036669. Epub 2012 May 10.


Gender specific differences in bladder cancer.

DeGraff DJ, Matusik RJ.

J Urol. 2012 Jul;188(1):10-1. doi: 10.1016/j.juro.2012.04.037. Epub 2012 May 13. No abstract available.


When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.

DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM.

Urol Oncol. 2013 Aug;31(6):802-11. doi: 10.1016/j.urolonc.2011.07.017. Epub 2011 Sep 15. Review.


Wnt/β-catenin activation promotes prostate tumor progression in a mouse model.

Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ.

Oncogene. 2011 Apr 21;30(16):1868-79. doi: 10.1038/onc.2010.560. Epub 2010 Dec 13.


Human homolog of Drosophila Hairy and enhancer of split 1, Hes1, negatively regulates δ-catenin (CTNND2) expression in cooperation with E2F1 in prostate cancer.

Lu JP, Zhang J, Kim K, Case TC, Matusik RJ, Chen YH, Wolfe M, Nopparat J, Lu Q.

Mol Cancer. 2010 Nov 24;9:304. doi: 10.1186/1476-4598-9-304.


Characterization of cis elements of the probasin promoter necessary for prostate-specific gene expression.

Zhang J, Gao N, DeGraff DJ, Yu X, Sun Q, Case TC, Kasper S, Matusik RJ.

Prostate. 2010 Jun 15;70(9):934-51. doi: 10.1002/pros.21128.


Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, Vasioukhin V, Matusik R.

Prostate. 2010 May 1;70(6):591-600. doi: 10.1002/pros.21093.


Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression.

Sun Q, Yu X, Degraff DJ, Matusik RJ.

Mol Endocrinol. 2009 Dec;23(12):2038-47. doi: 10.1210/me.2009-0092. Epub 2009 Oct 21.


Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.

Jiang M, Fernandez S, Jerome WG, He Y, Yu X, Cai H, Boone B, Yi Y, Magnuson MA, Roy-Burman P, Matusik RJ, Shappell SB, Hayward SW.

Cell Death Differ. 2010 Mar;17(3):469-81. doi: 10.1038/cdd.2009.148. Epub 2009 Oct 16.


Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer.

Yi Y, Nandana S, Case T, Nelson C, Radmilovic T, Matusik RJ, Tsuchiya KD.

Mol Cytogenet. 2009 Sep 26;2:18. doi: 10.1186/1755-8166-2-18.


Bladder stromal loss of transforming growth factor receptor II decreases fibrosis after bladder obstruction.

Anumanthan G, Tanaka ST, Adams CM, Thomas JC, Wills ML, Adams MC, Hayward SW, Matusik RJ, Bhowmick NA, Brock JW 3rd, Pope JC 4th.

J Urol. 2009 Oct;182(4 Suppl):1775-80. doi: 10.1016/j.juro.2009.05.126. Epub 2009 Aug 18.


Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling.

Li X, Wang Y, Sharif-Afshar AR, Uwamariya C, Yi A, Ishii K, Hayward SW, Matusik RJ, Bhowmick NA.

Differentiation. 2009 Jan;77(1):95-102. doi: 10.1016/j.diff.2008.09.012. Epub 2008 Oct 25.


Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration.

Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, Taketo MM, Wills M, Matusik RJ.

Prostate. 2009 Feb 15;69(3):249-62. doi: 10.1002/pros.20877.


Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells.

Thomas JC, Oottamasathien S, Makari JH, Honea L, Sharif-Afshar AR, Wang Y, Adams C, Wills ML, Bhowmick NA, Adams MC, Brock JW 3rd, Hayward SW, Matusik RJ, Pope JC 4th.

J Urol. 2008 Oct;180(4 Suppl):1784-9. doi: 10.1016/j.juro.2008.03.098. Epub 2008 Aug 21.


Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium.

Anumanthan G, Makari JH, Honea L, Thomas JC, Wills ML, Bhowmick NA, Adams MC, Hayward SW, Matusik RJ, Brock JW 3rd, Pope JC 4th.

J Urol. 2008 Oct;180(4 Suppl):1778-83. doi: 10.1016/j.juro.2008.04.076. Epub 2008 Aug 21.


The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ.

Cancer Res. 2008 Aug 15;68(16):6762-9. doi: 10.1158/0008-5472.CAN-08-0107.


Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.

Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, Shen MM, Matusik RJ, Hayward SW, Bhowmick NA.

Cancer Res. 2008 Jun 15;68(12):4709-18. doi: 10.1158/0008-5472.CAN-07-6289.


Down-regulation of p57Kip2 induces prostate cancer in the mouse.

Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P, Matusik RJ.

Cancer Res. 2008 May 15;68(10):3601-8. doi: 10.1158/0008-5472.CAN-08-0073.


Prostate epithelial cell fate.

Matusik RJ, Jin RJ, Sun Q, Wang Y, Yu X, Gupta A, Nandana S, Case TC, Paul M, Mirosevich J, Oottamasathien S, Thomas J.

Differentiation. 2008 Jul;76(6):682-98. doi: 10.1111/j.1432-0436.2008.00276.x. Epub 2008 May 7. Review.


PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity.

Levitin F, Weiss M, Hahn Y, Stern O, Papke RL, Matusik R, Nandana SR, Ziv R, Pichinuk E, Salame S, Bera T, Vincent J, Lee B, Pastan I, Wreschner DH.

J Biol Chem. 2008 Jun 13;283(24):16928-39. doi: 10.1074/jbc.M801454200. Epub 2008 Apr 3.


Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation.

Martinez-Ferrer M, Iturregui JM, Uwamariya C, Starkman J, Sharif-Afshar AR, Suzuki K, Visedsindh W, Matusik RJ, Dmochowski RR, Bhowmick NA.

Am J Pathol. 2008 Jan;172(1):59-67. Epub 2007 Dec 13.


Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.

Gupta A, Wang Y, Browne C, Kim S, Case T, Paul M, Wills ML, Matusik RJ.

Prostate. 2008 Jan 1;68(1):50-60.


Supplemental Content

Loading ...
Support Center